<DOC>
	<DOCNO>NCT01228370</DOCNO>
	<brief_summary>Because bladder neck proximal urethra contain abundant α1-adrenergic receptor , α-blockers α1-blockers well-known reduce bladder neck obstruction patient without neurogenic bladder . α1-blockers seem potential reduce bladder outlet resistance void patient neurogenic bladder . Based turnout , design clinical study evaluate clinical effect safety silodosin void dysfunction associate neurogenic bladder .</brief_summary>
	<brief_title>Efficacy Safety Silodosin Voiding Dysfunction Associated With Neurogenic Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Patient 20 year old Patient diagnose neurogenic bladder urodynamic test , urinary disorder symptom In case , patient take concomitant drug allow study , dose stable within 8 week screen visit Patient IPSS score 8 Patient QoL score 3 Patient Qmax 15 mL/sec Patient PSA &lt; 4.0 ng/mL PSA &gt; 4.0 ng/mL opinion prostate cancer biopsy Patient willing take investigational product accordance protocol Patient able fill questionnaire understand requirement study include inform consent Patient voluntarily decide participate sign write consent form . Patient h urinate his/her . Patient history bladder surgery Patient detrusor areflexia acontractile bladder diagnose urodynamic test Patient postvoid residual urine volume ( PRV ) 300 mL great , PRV 50 % maximum bladder capacity Patient prostate volume 30 mL great result severe benign prostatic hyperplasia ( BPH ) ( case male ) Patient urethral stricture Patient symptomatic urinary tract infection ( UTI ) screen visit Patient gross hematuria ( except idiopathic hematuria ) Patient conduct Clean Intermittent Catheterization ( CIC ) Patient take αblocker silodosin αagonist within 8 week screen visit Patient Botulinum toxin injection bladder problem within least 1 year screen visit Patient severe hapatic disorder ( hepatic insufficiency , cirrhosis , jaundice , hepatoma ) total bilirubin 2.5 mg/dL high AST/ALT 2.5 time higher normal upper limit Patient renal impairment serum creatinine 2.0 mg/dL high Patient experience severe arrhythmia , cardiac failure , myocardiac infarction , unstable angina , cerebral infarction within 6 month screen visit Patient orthostatic hypotention screen visit Patient demand chronic disease Patient allergy drug Patient prohibit take silodosin Patient take drug prohibit study clinical study Patient pregnant plan pregnant breastfeed practice contraception use medically acceptable contracenption Patient experience clinical study within 4 week screen visit Patient exclude medical dicisions make investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>sildosin</keyword>
	<keyword>neurogenic bladder</keyword>
	<keyword>void dysfunction</keyword>
</DOC>